- * Diagnosis of sickle cell disease with the homozygous HbS homozygous genotype (HbSS) or an HbSβ thalassemia variant (ie, HbSβ0 thalassemia or HbSβ+ thalassemia) genotype, confirmed by hemoglobin studies.
- * Fetal hemoglobin (HbF) ≤ 15%.
- * Severe sickle cell disease symptomatology, defined as any one or more of the following:
- 1. ≥ 2 episodes of acute chest syndrome in the last 2 years.
- 2. ≥ 3 episodes of severe pain events requiring a visit to a medical facility and treatment with opioids in the last 2 years.
- 3. \> 2 episodes of recurrent priapism in the last 2 years.
- 4. Red-cell alloimmunization (\> 2 antibodies) during long-term transfusion therapy (lifetime history).
- 5. Chronic transfusions for primary or secondary prophylaxis (lifetime history).
- 6. Trans-thoracic echocardiograph evidence of tricuspid valve regurgitant jet velocity ≥ 2.7 m/sec (lifetime history).
- 7. Clinically significant neurologic event (eg, ischemic stroke) or any neurological deficit lasting \> 24 hours.
- * Not eligible for human leukocyte antigen (HLA)-matched hematopoietic stem cell transplantation, defined as follows: no medically eligible, available, and willing 10/10 matched HLA-identical sibling donor, unless subject has declined this treatment option (as documented in the informed consent form).
- * Not eligible for, declined, or, as judged by the investigator, failed therapy with hydroxyurea and if still on hydroxyurea is able to interrupt hydroxyurea starting at the beginning of the transfusions, before mobilization and apheresis.
Anemia, Sickle Cell
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
NCT04091737 | PHASE 1 | INTERVENTIONAL
This is a phase 1 pilot study of CSL200 in adult subjects with severe sickle cell disease. The primary objectives of this study are to evaluate the safety of the following: collection of CD34+ hematopoietic stem / progenitor cells by apheresis after mobilization with plerixafor, reduced intensity conditioning with melphalan, and administration of CSL200.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
City of Hope Medical Center
Duarte,California,United States,91010
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov